QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immmunization in humans

Academic Article

Abstract

  • Three separate studies were undertaken in HIV-1 uninfected persons to determine if the adjuvant QS-21 improves the magnitude or kinetics of immune responses induced by recombinant soluble gp120 HIV-1MN protein (rsgp120) immunization. The QS-21 was administered at two doses (50 and 100 μg), either alone or in combination with aluminum hydroxide (600 μg). At the highest doses of rsgp120 (100, 300, and 600 μg), QS-21 exerted no significant effect on either binding or neutralizing antibody titers. Antibody binding and neutralizing responses fell dramatically when rsgp120, formulated with alum alone, was given at low doses (3 and 30 μg). In contrast, antibody responses similar in titer to those in the high dose antigen groups were induced with the low dose rsgp120 formulated with QS-21. In addition, the lymphocyte proliferation and delayed type hypersensitivity skin testing were superior in the QS-21 recipients compared with the alum recipients at the low antigen doses. Moderate to severe pain was observed in majority of the volunteers receiving QS-21 formulations, and vasovagal episodes and hypertension were not infrequent. Thus, the use of QS-21 may provide a means to reduce the dose of a soluble protein immunogen. © 2001 Elsevier Science Ltd.
  • Published In

  • Vaccine  Journal
  • Digital Object Identifier (doi)

    Author List

  • Evans TG; McElrath MJ; Matthews T; Montefiori D; Weinhold K; Wolff M; Keefer MC; Kallas EG; Corey L; Gorse GJ
  • Start Page

  • 2080
  • End Page

  • 2091
  • Volume

  • 19
  • Issue

  • 15-16